Lv41
680 积分 2023-03-16 加入
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1小时前
已完结
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
15天前
已完结
An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer
1个月前
已完结
Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectives
3个月前
已关闭
Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals
3个月前
已关闭
中国肿瘤药物相关血小板减少诊疗专家共识（2023版）
3个月前
已完结
Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer
3个月前
已完结
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study)
3个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
4个月前
已完结
Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy
4个月前
已完结
皖公网安备34019202002308
